{
    "name": "ezetimibe",
    "comment": "Rx",
    "other_names": [
        "Zetia"
    ],
    "classes": [
        "Lipid-Lowering Agents",
        "2-Azetidinones"
    ],
    "source": "https://reference.medscape.com/drug/zetia-ezetimibe-342454",
    "pregnancy": {
        "common": [
            "Pregnancy category: C",
            "Lactation: Excretion in milk unknown; use with caution"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Excretion in milk unknown; use with caution"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Coadministration with a statin in the presence of active liver disease or persistent, unexplained elevations of hepatic transaminase levels"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Elevated hepatic transaminases (≥3 X ULN) reported with concomitant use of statins compared to statin monotherapy; consider discontinuation of therapy (ezetimibe and/or statin) for persistently elevated transaminases (ALT or AST (≥3 X ULN)",
                "Myopathy, including rhabdomyolysis reported with monotherapy (rare); risk increased with concomitant use of statin or fibrate immediately if myopathy suspected or confirmed (symptomatic patient with CPK >10 X ULN)",
                "Hepatic impairment may increase systemic exposure; use with caution in patient swith mild hepatic impairment (Child-Pugh class A); use not recommended in patients with moderate to severe hepatic impairment (Child-Pugh classes B and C)",
                "Use with caution in patients with severe renal impairment (CrCl ≤30 mL/min/1.73 m²); if using concurrent simvastatin in patients with moderate to severe renal impairment (CrCl<60 mL/min/1.73 m²) use caution with simvastatin doses exceeding 20 mg; monitor for adverse events",
                "Cholelithiasis reported (when coadministered with fibric acid derivatives)",
                "Rule out secondary causes of hyperlipidemia prior to therapy"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "cyclosporine, ezetimibe.\nEither increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Monitor for potential adverse effects of cyclosporine and ezetimibe if coadministered, especially in patients with severe renal impairment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "leniolisib",
            "description": {
                "common": "leniolisib will increase the level or effect of ezetimibe by  Other (see comment). Avoid or Use Alternate Drug. Leniolisib, an OATP1B1 and OATP1B3 inhibitor, may increase systemic exposure of these substrates "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trofinetide",
            "description": {
                "common": "trofinetide will increase the level or effect of ezetimibe by  Other (see comment). Avoid or Use Alternate Drug. Trofinetide (an OATP131 and OATP13B inhibitor) may increase plasma levels of OATP131 or OATP13B substrates. Avoid coadministration with sensitive substrates."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "zavegepant intranasal",
            "description": {
                "common": "ezetimibe will increase the level or effect of zavegepant intranasal by  Other (see comment). Avoid or Use Alternate Drug. NTCP inhibitors may result in a significant increase in systemic exposure of zavegepant (a NTCP substrate)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of ezetimibe by  increasing elimination. Use Caution/Monitor. Apalutamide induces UGT and weakly induces OATP1B1 and may decrease systemic exposure of drugs that are substrates of both UGT and OATP1B1."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholestyramine",
            "description": {
                "common": "cholestyramine decreases levels of ezetimibe by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2-4 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "encorafenib",
            "description": {
                "common": "encorafenib will increase the level or effect of ezetimibe by  Other (see comment). Modify Therapy/Monitor Closely. Encorafenib (a OATP1B1 inhibitor) may increase the concentration and toxicities of OATP1B1 substrates. Closely monitor for signs and symptoms of increased exposure and consider adjusting the dose of these substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fostemsavir",
            "description": {
                "common": "fostemsavir will increase the level or effect of ezetimibe by  Other (see comment). Modify Therapy/Monitor Closely. Fostemsavir inhibits OATP1B1/3 transporter. If possible, avoid coadministration or modify dose of OATP1B1/3 substrates coadministered with fostemsavir."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glecaprevir/pibrentasvir",
            "description": {
                "common": "glecaprevir/pibrentasvir will increase the level or effect of ezetimibe by  Other (see comment). Use Caution/Monitor. Coadministration with glecaprevir/pibrentasvir may increase plasma concentration of drugs that are substrates of OATP1B1 or OATP1B3"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "letermovir",
            "description": {
                "common": "letermovir increases levels of ezetimibe by Other (see comment). Use Caution/Monitor. \nComment: Letermovir, an OATP1B1/3 inhibitor may increase plasma concentrations of coadministered OATP1B1/3 substrates."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sofosbuvir/velpatasvir",
            "description": {
                "common": "sofosbuvir/velpatasvir increases levels of ezetimibe by Other (see comment). Use Caution/Monitor. \nComment: Velpatasvir inhibits OATP1B1, OATP1B3, and OATP2B1 transporters. ."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fenofibrate",
            "description": {
                "common": "fenofibrate increases levels of ezetimibe by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fenofibrate micronized",
            "description": {
                "common": "fenofibrate micronized increases levels of ezetimibe by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fenofibric acid",
            "description": {
                "common": "fenofibric acid increases levels of ezetimibe by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "gemfibrozil",
            "description": {
                "common": "gemfibrozil increases levels of ezetimibe by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin will increase the level or effect of ezetimibe by  Other (see comment). Minor/Significance Unknown. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Monitor for adverse reactions of OATP1B1 substrates when coadministered with voclosporin."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Diarrhea",
            "percent": "4"
        },
        {
            "name": "Upper respiratory tract symptoms",
            "percent": "2-4"
        },
        {
            "name": "Cough",
            "percent": "2-4"
        },
        {
            "name": "Pain in extremity",
            "percent": "3"
        },
        {
            "name": "Sinusitis",
            "percent": "3"
        },
        {
            "name": "Arthralgia",
            "percent": "2-3"
        },
        {
            "name": "Fatigue",
            "percent": "2"
        },
        {
            "name": "Influenza",
            "percent": "2"
        },
        {
            "name": "Increased liver transaminases",
            "percent": "3"
        },
        {
            "name": "with HMG",
            "percent": "1"
        },
        {
            "name": "CoA reductase inhibitors",
            "percent": null
        },
        {
            "name": "x ULN",
            "percent": null
        },
        {
            "name": "Hepatitis",
            "percent": null
        },
        {
            "name": "liver function test abnormalities",
            "percent": null
        },
        {
            "name": "LFTs elevated slightly higher in combination with statin than with statin alone",
            "percent": null
        },
        {
            "name": "Hypersensitivity reactions",
            "percent": null
        },
        {
            "name": "including anaphylaxis",
            "percent": null
        },
        {
            "name": "angioedema",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "Erythema multiforme",
            "percent": null
        },
        {
            "name": "Elevated creatine phosphokinase",
            "percent": null
        },
        {
            "name": "Myopathy",
            "percent": null
        },
        {
            "name": "rhabdomyolysis",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "Back pain",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "Pancreatitis",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Paresthesia",
            "percent": null
        },
        {
            "name": "Depression",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Cholelithiasis and cholecystitis",
            "percent": null
        }
    ]
}